LC
BHVN

Lindbrook Capital’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Lindbrook Capital’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-491
Closed -$74K – 3094
2022
Q3 		$74K Buy
491
+118
+32% +$17.5K 0.01% 532
2022
Q2 		$54K Sell
373
-239
-39% -$30.5K 0.01% 631
2022
Q1 		$73K Sell
612
-206
-25% -$25.7K 0.01% 566
2021
Q4 		$113K Buy
+818
New +$104K 0.02% 462

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Lindbrook Capital's BHVN Position: Q4 2022 in Review

Lindbrook Capital sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 491 shares — an estimated $74K sold.

Lindbrook Capital first reported a position in BHVN in Q4 2021 and held it in 4 quarters. The position peaked at $113K in Q4 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Lindbrook Capital reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Lindbrook Capital sold 491 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $74K.
  • Lindbrook Capital first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2021 and held it in 4 quarters.
  • Lindbrook Capital's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $113K in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Lindbrook Capital's 13F filing for Q4 2022, filed 25 Jan 2023.